Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

The approval of EYLEA was granted under a Priority Review, a designation that is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.  This approval was based upon the results of two Phase 3 clinical studies.  In these studies, EYLEA dosed every eight weeks, following three initial monthly injections, was clinically equivalent to the standard of care, Lucentis® (ranibizumab injection) dosed every four weeks, as measured by the primary endpoint of maintenance of visual acuity (less than 15 letters of vision loss on an eye chart) over 52 weeks.  The most common adverse reactions (frequency of 5% or more) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.  The adverse event profile was similar to that seen with ranibizumab.

"The approval of EYLEA offers a much needed new treatment option for patients with wet AMD," said Jeffrey Heier, M.D., a clinical ophthalmologist and retinal specialist at Ophthalmic Consultants of Boston, Assistant Professor of Ophthalmology at Tufts School of Medicine, and Chair of the Steering Committee for the VIEW 1 trial.
"EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and no monitoring requirements.  This may reduce the need for cos
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 Juno Therapeutics today announced ... to the company,s JCAR015 chimeric antigen receptor product ... relapsed or refractory B-cell acute lymphoblastic leukemia and ... Kettering Cancer Center, where Phase 1 clinical trials ... action is important news for patients who may ...
(Date:11/24/2014)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced today that Sergio Traversa , chief executive ... "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, ... Sunset Bel Air Hotel, which is located at 11461 ... . The presentation is scheduled for 8:30 ...
(Date:11/24/2014)... , Nov. 24, 2014  GlySens Incorporated announced ... million dollar grant from the National Institute of Diabetes ... the National Institutes of Health (NIH).  The grant is ... second generation ICGM™ long term implantable glucose monitoring system.  ... and enrollment is expected to begin before the end ...
Breaking Medicine Technology:Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... ,, MINNEAPOLIS , July 8 Protectus Medical Devices, ... today it has received Notice of Allowance from the US Patent and ... self-sheathing Safety Syringe, a major step toward it becoming the ... , , ...
... Profil™ Institute for Clinical Research, Inc., a company specializing in early ... Marcus Hompesch , the company,s President and CEO, will serve as ... Diabetes, the American Diabetes Association,s ( ADA ) largest fund-raising event. ... Dr. Hompesch will help ...
Cached Medicine Technology:US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 3Profil Institute Teams Up With American Diabetes Association to 'Step Out' Against Diabetes 2Profil Institute Teams Up With American Diabetes Association to 'Step Out' Against Diabetes 3
(Date:11/26/2014)... November 26, 2014 Medical suction and ... out of 5. This score represents steady growth in ... years to 2014 as a result of swelling demand ... machines, which are largely considered nondiscretionary. IBISWorld market research ... buyers have some degree of flexibility, given the low ...
(Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Vultures have developed highly specialized ... when eating dead animals, researchers report. The new ... the faces and in the guts of 50 turkey ... average, the faces of the vultures had more than ... their guts, the study found. The findings suggest ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 ... Food and Drug Administration will have many restaurant chains posting ... to movie theater popcorn and ice cream parlor fare. ... home, often consuming less nutritious food and underestimating the calories ... Monday afternoon news conference. Although listing calorie counts ...
(Date:11/24/2014)... From embedded sensors and biometrics to elite training ... take center stage at the FitnessTech Summit , presented ... 2015 International CES® , January 6, 2015 in Las Vegas ... The bond between fitness and technology is stronger than ever ... more about the human body. , “Fitness technology has become ...
Breaking Medicine News(10 mins):Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4
... Fitness announced,that it has successfully emerged from chapter ... months after filing for bankruptcy protection on July ... Partners,Master Fund I, Ltd. and Harbinger Capital Partners ... Harbinger invested approximately $233.6 million in exchange for ...
... A visionary leader, Dr.,Maria Cristina Escobar ... outstanding contributions to the prevention and control ... 27th Pan American Sanitary Conference,proceedings today. The ... is bestowed upon creative leaders whose commitment ...
... With record supplies,of influenza vaccine expected to be ... Johnson today urged Pennsylvanians -- especially,those in high- ... by,getting a flu shot. "The flu is ... children and individuals with certain medical conditions,",explained Dr. ...
... (Nasdaq: LMAT ), a provider of peripheral vascular ... agreement to launch a,direct sales force in Italy in ... in Italy through an,exclusive distribution agreement with Serom Medical ... exclusive rights on,January 25, 2008 in exchange for the ...
... are chronically infected with hepatitis B will die from its ... Stanford University School of Medicine has identified the most cost-effective ... hepatitis B often don,t know it, because they can go ... group most likely to be infected with hepatitis B - ...
... entities in the addiction treatment field announced the launch ... (ACTION) Campaign for the improvement of addiction treatment services. ... addiction treatment for individuals in need and to keep ... during National Recovery Month in September, has a goal ...
Cached Medicine News:Health News:Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds 2Health News:Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds 3Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:Health Secretary Urges Pennsylvanians to Get a Flu Shot 2Health News:LeMaitre Vascular to Start Italian Sales Force 2Health News:LeMaitre Vascular to Start Italian Sales Force 3Health News:Stanford researchers find way to fight treacherous hepatitis B 2Health News:Stanford researchers find way to fight treacherous hepatitis B 3Health News:Stanford researchers find way to fight treacherous hepatitis B 4Health News:Leaders in addiction treatment announce national 'ACTION' campaign 2
...
...
... an easy way to eliminate paper ECG ... money. This Windows-based tool dramatically streamlines ECG ... and the hospital emergency department. You can ... Review high-resolution waveforms on-screen. Edit patient information, ...
... communications software, including Remote Link and Central ... you the tools and choices to effectively ... Send patient tests via email, LAN or ... Philips Zymed Holter analysis applications are used. ...
Medicine Products: